View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet
Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet
ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Company comments AB InBev: Little to disappoint Adyen: 2H25 results – mixed results, soft guidance CVC Capital Partners: Executing well dsm-firmenich: Messy results Fagron: Beat on all lines, confident FY26 outlook to drive c.5% consensus EBITDA upgrade Flow Traders: EMEA saves the day KBC: Good results, opening up “jaws” further to 2028 Kinepolis: Canadian peer Cineplex 4Q25 results below consensus, January 2026 box office revenue up MICC: FX headwind leads to a 50bp margin miss in FY25 Montea:...

 PRESS RELEASE

Ipsen delivers strong results in 2025, driven by solid execution acros...

Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance FY 2025 sales growth of 10.9% at CER1, or 8.1% as reported, driven by growth of the three therapeutic areas of Oncology (4.1%1), Rare Disease (102.5%1) and Neuroscience (9.7%1); Somatuline® sales growth of 4.3%1, with all other products, excluding Somatuline, achieving double-digit sales growth of 14.2%1FY 2025 core operating income of €1,294m, growing by 16.7% as reported, with a core operating margin of 35.2% of total sales, increasing by 2.6 points2025 continued pipel...

 PRESS RELEASE

Ipsen réalise de solides résultats en 2025, grâce à une performance so...

Ipsen réalise de solides résultats en 2025, grâce à une performance soutenue de toutes les aires thérapeutiques, et annonce ses objectifs 2026 Croissance des ventes totales du Groupe en 2025 de 10,9% à taux de change constant1 (8,1% en données publiées), tirée par la croissance des trois aires thérapeutiques avec une croissance de 4,1%1 en Oncologie, 102,5%1 dans les Maladies Rares et 9,7%1 en Neurosciences. Croissance des ventes de Somatuline® de 4,3%1, tandis que le portefeuille de médicaments hors Somatuline, affiche une croissance à deux chiffres de 14,2%1 Résultat opérationnel des acti...

 PRESS RELEASE

Designated person notification

Designated person notification 11 February 2026, 16:30 CET With reference to Article 19(3) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulations), ArcelorMittal announces that notification of share transaction by a Designated Person (i.e. Directors or Executive Officers) is available in the Luxembourg Stock Exchange’s electronic database OAM on and on ArcelorMittal’s web site under Investors > Share Transactions by Management: ENDS About ArcelorMittal ArcelorMittal is one of the world’s leading integrat...

Carole Braudeau
  • Carole Braudeau

Credit Morning 02/11/2026

Imerys: French State is investing in the Emili Lithium Project|Downgrade from BB-/negative CW to B/negative outlook by Fitch|

Carole Braudeau
  • Carole Braudeau

Morning Crédit 11/02/2026

Imerys : l’Etat entre au capital du projet EMILI (lithium)|Downgrade de la note de 'BB-' CW négatif à B/outlook négatif par Fitch|

 PRESS RELEASE

ArcelorMittal confirms the construction of an electric arc furnace in ...

ArcelorMittal confirms the construction of an electric arc furnace in Dunkirk, France: a €1.3 billion investment supporting an important step in its decarbonisation 10 February 2026, 12:15 CET ArcelorMittal today confirms the construction of an electric arc furnace (EAF) at its steelmaking site in Dunkirk – a strategic €1.3 billion investment which marks a major step in the decarbonisation of ArcelorMittal’s steel production in France. ArcelorMittal is delighted to welcome the French President, Emmanuel Macron, to its Dunkirk site today. President Macron, accompanied by Roland Lescure, Mi...

Carole Braudeau
  • Carole Braudeau

Credit Morning 02/10/2026

NIH: SNCF ordered to pay € 270m in compensation in the Gare du Nord case|Clarifications from Eramet on the temporary exemption of duty of its CFO|

Carole Braudeau
  • Carole Braudeau

Morning Crédit 10/02/2026

NIH : la SNCF condamnée à verser une indemnité de 270 m EUR dans le dossier de la Gare du Nord|Clarifications d’Eramet sur la dispense d’activité temporaire de son CFO|

 PRESS RELEASE

Ipsen - January 2026 - Monthly information relative to the total numbe...

Ipsen - January 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights (1)31 January 202683,814,526Gross total* of voti...

 PRESS RELEASE

Ipsen - Janvier 2026 - Information mensuelle relative au nombre total ...

Ipsen - Janvier 2026 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Information mensuelle relative au nombre total des droits de voteet d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerceet à l’article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : Euronext Paris Code ISIN : FR 0010259150LEI : 549300M6SGDPB4Z94P11 Date Nombre total d’actions composant le capital socialNombre total de droits de vote (1)31 janvier 202683 814 526Total brut* des droit...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch